Rural Cancer Patients in the US Face Extreme Travel Burdens to Access Treatment

For roughly 60 million Americans living in rural communities, a cancer diagnosis comes with a burden that urban patients rarely face: the sheer geography between home and treatment. While a patient in Dallas or Atlanta can reach an oncologist's office in a 15-minute drive, their counterparts in rural Texas or the Mississippi Delta may need to travel 80 miles or more each way — and repeat that trip dozens of times over the course of chemotherapy or radiation [1][2]. The result is a system where survival can depend less on the biology of a tumor than on how far you live from the nearest specialist.

The Distance Problem, by the Numbers

The scale of the access gap is stark. An estimated 20% of rural residents live more than 60 miles from the nearest medical oncologist [1]. In frontier counties — the most sparsely populated designation — median one-way travel to an oncologist reaches 120 miles [2]. Urban patients, by contrast, face a median trip of about 15 miles.

Source: Rural Health Information Hub / JAMA Network Open

Data as of Jan 1, 2025CSV

Only 3% of medical oncologists practice in rural areas, even though 20% of the U.S. population lives there [3]. Over 70% of U.S. counties have no medical oncologist at all, and just 16% of radiation oncologists work outside metropolitan regions [3]. The downstream effect: patients in small towns travel nearly three times longer than urban residents to reach radiotherapy, and those seeking care at academic cancer centers face drives averaging 83 to 97 minutes each way [3].

A 2025 study published in JAMA Network Open found that over 7% of Medicare cancer patients cross state lines for treatment — a figure that nearly doubles for rural patients [4]. In states like Wyoming, Montana, and the Dakotas, crossing into a neighboring state for chemotherapy is routine, not exceptional.

A Financial Spiral Beyond Medical Bills

The travel burden compounds an already heavy financial load. About 50.5% of rural cancer survivors report financial problems stemming from their illness, compared with 38.8% of urban survivors [5].

Source: PMC / National Sample Survey

Data as of Jan 1, 2024CSV

The costs extend well past copays and deductibles. Transportation is one of the largest direct nonmedical costs of cancer care, with patients' monthly out-of-pocket nonmedical expenses averaging $213, ranging up to $587 [6]. For a rural patient making weekly trips of 160 miles round-trip for six weeks of radiation, fuel costs alone can exceed $1,000 — before accounting for lodging, meals, or lost wages.

Rural per-capita income averaged $45,917 in 2020, compared with $61,717 in urban areas [7]. More rural workers are self-employed or employed by small businesses, meaning they often lack protections under the Family and Medical Leave Act and face direct income loss when they miss work for treatment [6]. Over 43% of privately insured rural cancer survivors carry high-deductible health plans, and 17.4% have skipped or delayed medications because of cost [7]. Nearly one in five delayed medical care entirely due to expense [7].

The personal toll can be catastrophic in individual cases. One rural patient profiled by the American Cancer Society Cancer Action Network accumulated $800,000 in medical debt after a bone marrow transplant, against a backdrop of limited local options [7].

The Cancers Hitting Rural America Hardest

Rural populations face disproportionately high rates of cancers linked to smoking and those preventable through screening. Lung cancer incidence is 29.8% higher in rural counties than metropolitan ones, and lung cancer mortality is 20.3% higher [8]. Colorectal and cervical cancer rates are also elevated in rural areas, driven by higher tobacco use, lower screening rates, lower HPV vaccination uptake, and reduced access to preventive care [8][9].

Overall cancer incidence is modestly higher in rural areas — 460 per 100,000 versus 447 in metropolitan counties — but the mortality gap is wider [8]. Rural residents have a 2.7% increased risk of developing cancer and a 9.6% higher risk of dying from it [10]. Between 2004 and 2013, age-adjusted cancer death rates fell at -1.0% per year in rural areas versus -1.6% in metro areas, meaning the gap has been growing [10].

Whether travel access alone explains this survival difference remains an open question. Research has found that patients traveling more than 50 miles to a diagnostic facility are more likely to present with metastatic disease [10]. Later-stage diagnosis, delayed chemotherapy initiation, and higher rates of declining treatment altogether have all been associated with greater travel distance [10]. But isolating travel from confounding factors — income, insurance status, comorbidities, smoking rates — is methodologically difficult, and no single study has shown that eliminating travel burden alone would close the rural-urban mortality gap.

A Shrinking Safety Net: Rural Hospital Closures

The infrastructure supporting rural cancer care has been contracting for over a decade. Since 2010, 182 rural hospitals have closed or converted to models that exclude inpatient care — roughly 10% of the nation's rural hospitals [11].

Source: Chartis Center for Rural Health

Data as of Jan 1, 2025CSV

Texas leads the losses with 26 communities that have lost inpatient care, followed by Tennessee at 16. Georgia, Kansas, Mississippi, Missouri, and Oklahoma have each lost inpatient care in 11 communities [11]. The geographic pattern concentrates in the South, from the Carolinas through Texas, and extends into the rural Midwest.

The oncology-specific losses are even more striking. Between 2014 and 2023, 424 rural hospitals stopped providing chemotherapy services — 21% of all rural hospitals that had offered them [11]. Texas alone lost 61 chemotherapy-providing facilities; Oklahoma lost 29 [11]. Another 432 rural hospitals are currently classified as vulnerable to closure [11].

For patients in counties that lost a local facility, the consequences are immediate and measurable: longer drives, more missed appointments, and a higher likelihood of foregoing treatment entirely.

The Consolidation Argument: Volume vs. Access

Proponents of centralizing cancer care into high-volume regional centers make a genuine evidence-based case. Patients treated at high-volume surgical centers show decreased 30- and 90-day mortality, higher rates of complete tumor resection, and improved overall survival [12]. For breast cancer, treatment at high-volume centers is associated with 11% lower overall mortality [13]. Specific volume thresholds have been identified: 17 gastrectomies per year for gastric cancer, 25 cases for pancreaticoduodenectomy, 18 for esophagectomy [12].

For complex surgical oncology — pancreatic, esophageal, and hepatobiliary cancers — the case for regionalization is strong. These are procedures where surgical skill and institutional experience have a measurable impact on whether patients survive.

But the argument weakens for more common cancers and nonsurgical treatment. Standard chemotherapy regimens for breast, colorectal, and lung cancer do not require the specialized infrastructure of an academic medical center. A 2026 analysis by the American College of Surgeons found that rural cancer patients undergoing surgery at local facilities had outcomes comparable to those at distant high-volume centers for several common procedures [14]. The trade-off between volume-driven quality and access-driven completion rates is not resolved by a single policy answer — it depends on the cancer type and the treatment modality.

Federal Dollars: Who Benefits?

Several federal programs aim to sustain rural oncology access, but the evidence on whether they reach patients is mixed.

The 340B Drug Pricing Program allows eligible hospitals to purchase outpatient drugs, including expensive oncology medications, at steep discounts. Hospitals that enrolled in 340B between 2012 and 2018 were 8.3 percentage points more likely to have added oncology services by 2020 [15]. But the newly participating hospitals that added oncology were disproportionately located in Medicaid expansion states and counties with lower uninsurance rates — not the most disadvantaged rural communities [15]. A Congressional Budget Office report documented significant growth in 340B program spending, raising questions about whether the savings flow to patients or to hospital margins [16].

Medicare rural add-on payments provide supplemental reimbursement to rural hospitals, and Critical Access Hospital designation offers cost-based reimbursement to facilities meeting distance and size criteria. These programs help keep small hospitals viable, but do not specifically target oncology services.

The USDA Distance Learning and Telemedicine Grants allocated approximately $40 million for fiscal year 2025, with individual grants ranging from $50,000 to $1 million [17]. These fund telehealth infrastructure but are not oncology-specific, and their impact on cancer treatment access has not been rigorously evaluated.

The total annual federal spend across these programs reaches into the billions, but there is no consolidated accounting of how much specifically supports rural oncology. The gap between program existence and patient-level impact remains a persistent criticism from rural health advocates.

Telehealth and Mobile Units: Promise and Limits

Teleoncology — using videoconferencing for remote consultations with cancer specialists — has shown real benefits. Studies demonstrate reduced wait times, faster diagnosis and treatment initiation, improved symptom management, and lower rates of emergency department visits and hospitalizations among patients receiving concurrent telehealth [18][19]. Patient satisfaction rates are consistently high, and a randomized trial of 162 patients across four rural oncology clinics found equivalent satisfaction and decreased costs for virtual cancer genetic counseling [18].

Mobile chemotherapy units, tested primarily in the United Kingdom, have delivered care that is less expensive, equal in quality, and more efficient than fixed-site alternatives [18].

But significant barriers limit wider adoption. Broadband access remains uneven in rural America. While rural residents are just as likely to own devices capable of telehealth, they face persistent internet access barriers that reduce actual utilization [17]. Only 54 published studies have examined technology use in rural cancer care delivery, representing a thin evidence base for scaling these interventions [18].

The most fundamental constraint is biological: many cancer treatments require physical administration. Intravenous chemotherapy, radiation therapy, and surgical procedures cannot be delivered through a screen. Telehealth can reduce the number of in-person visits for consultations, follow-ups, and symptom management, but it cannot replace the trips that matter most.

Regulatory barriers add friction. State licensing requirements complicate cross-border telehealth, particularly relevant for the rural patients who already cross state lines for in-person care [4]. Although pandemic-era waivers expanded telehealth access, the permanence of those flexibilities remains uncertain.

The Most Vulnerable Within the Vulnerable

Within the rural cancer population, certain groups face compounding barriers that push treatment access further out of reach.

American Indian and Alaska Native populations have the lowest cancer survival rates of any racial or ethnic group in the United States [20]. Cancer death rates among AI/AN individuals are approximately twice those of White Americans for several cancer types [20]. More than half (54%) of non-Hispanic AI/AN individuals live in rural areas or small towns, compared with 26% of non-Hispanic White individuals [21]. Indian Health Service facilities often lack cancer screening capabilities, and approximately one-third of IHS patients are uninsured [21]. AI/AN patients are less likely to undergo recommended surgeries, chemotherapy, and radiation, with barriers compounded by long distances to providers, limited transportation, and documented medical mistrust rooted in historical experience [20][22].

Farmworkers and agricultural laborers, many of whom are uninsured or undocumented, face barriers that extend beyond geography. Language access, fear of immigration enforcement, seasonal work patterns that make sustained treatment schedules difficult, and exclusion from employer-based insurance all contribute to lower screening rates and delayed diagnoses [9].

Elderly patients without drivers represent another high-risk group. Over 1.6 million rural households lack a personal vehicle [3]. Public transportation serves only about 60% of rural counties, and less than 10% of federal transit funding reaches rural areas [3]. For an 80-year-old patient living alone in a county without public transit, a weekly 160-mile round trip for radiation is not a logistical inconvenience — it is a practical impossibility.

What Closing the Gap Would Require

Source: U.S. Census Bureau / ACS 1-Year

Data as of Dec 31, 2023CSV

The states with the highest poverty rates — Mississippi, Louisiana, New Mexico, West Virginia, Kentucky — overlap substantially with those experiencing the greatest rural hospital losses and the widest cancer mortality gaps. This is not coincidence. Rural cancer care access is inseparable from the broader economics of rural America.

Addressing the travel burden requires action on multiple fronts: sustaining and expanding the oncology workforce in rural areas, investing in broadband infrastructure that makes telehealth viable, designing transportation assistance programs that match the actual distances involved, and critically evaluating whether federal subsidy dollars are reaching the patients and communities most in need.

The evidence does not support a single solution. Consolidating complex surgical cases at high-volume centers saves lives. Maintaining local capacity for standard chemotherapy and follow-up care prevents patients from abandoning treatment. Telehealth fills gaps for consultations and monitoring but cannot replace infusion chairs.

What the evidence does show clearly is the cost of inaction. Every year, the rural-urban cancer mortality gap widens. Every closed hospital adds miles to someone's treatment journey. And for the patients making those drives — or choosing not to — the arithmetic is simple: distance is not just an inconvenience. It is a determinant of survival.